Related Experiment Video
Updated: Jan 17, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
Evolutionary hallmark-inspired identification of prognostic biomarkers and drug targets for cancers
Yang He1, Chen-Wei Zhou1, Zhi-Wen Zhang1
1Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070 PR, China.
Abstract:
Identifying prognostic biomarkers and drug targets is important for cancer treatment. Accumulating evidence indicates that cancer progression reflects the reactivation of ancestral cellular programs, with evolutionarily ancient genes exerting a pivotal influence on tumor development. These ancient genes are markedly enriched among clinically validated biomarkers and therapeutic targets, highlighting their essential contribution to cancer pathogenesis and therapeutic development. The transcriptome age index (TAI) provides a quantitative framework to characterize transcriptome evolutionary dynamics, with demonstrated prognostic relevance across multiple cancer types. This review underscores the value of the TAI in shaping an evolutionary perspective for biomarker discovery and drug target identification, and considers its potential to advance precision oncology and future therapeutic development.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer
Cancer Survival Analysis
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

